| 000 | 01473cam a2200289 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223032031.0 | ||
| 008 | 180814s2017 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aGift | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.34.M.Sc.2017.Me.D | ||
| 100 | 0 | _aMennat Alaah saeed saad Hany | |
| 245 | 1 | 0 |
_aDesign and synthesis of novel SERMs and their evaluation as serotonin receptor ligands / _cMennatalaah saeed saad Hany ; Supervised Ashraf H. Abadi , Nermin S. Ahmed |
| 246 | 1 | 5 | _aتصميم وتشييد نظائر من مستقبلات الاستروجين الانتقائية الجديدة وتقييمها بروابط مستقبلات السيروتونين |
| 260 |
_aCairo : _bMennat Alaah saeed saad Hany , _c2017 |
||
| 300 |
_a93 Leaves : _bcharts , facsimiles ; _c30cm |
||
| 502 | _aThesis (M.Sc.) - German university - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceutical Chemistry | ||
| 520 | _aTomoxifen is the first-line endocrine therapy for the treatment of breast cancer. It is metabolized to more active forms 4-hydroxytamoxifan and 4-hydroxy N-desmethy1 tamoxifen (Endoxifen) by different cytochrome P450 enzymes | ||
| 700 | 0 |
_aAshraf H.Abadi , _eSupervisor |
|
| 700 | 0 |
_aNermin S. Ahmed , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aShimaa _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c67062 _d67062 |
||